Posted by Michael Wonder on 10 Oct 2025
Adcendo ApS announces FDA fast track designation granted to ADCE-D01 for the treatment of soft tissue sarcoma
9 October 2025 - Adcendo ApS today announced that the US FDA has granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.
ADCE-D01 is a first in class ADC targeting urokinase plasminogen activator receptor-associated protein conjugated to the topoisomerase I inhibitor payload P1021.
